vatalanib has been researched along with Kahler Disease in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amador-Ortiz, C; Ansstas, G; Bryant, G; Hassan, A; Mosley, JC; Procknow, E; Vij, R | 1 |
| Batey, MA; de Brito, LR; Hall, AG; Irving, JA; Jackson, G; Leung, HY; Maitland, H; Newell, DR; Squires, MS; Zhao, Y | 1 |
| Anderson, KC; Podar, K | 1 |
| Anderson, KC; Davies, F; Griffin, JD; Gupta, D; Hideshima, T; Lentzsch, S; Li, C; Li, S; Lin, B; Munshi, NC; Podar, K; Richardson, PG; Schlossman, RL; Tai, YT; Weisberg, E; Weller, E; Wood, J | 1 |
| Anderson, KC; Hayashi, T; Hideshima, T | 1 |
2 review(s) available for vatalanib and Kahler Disease
| Article | Year |
|---|---|
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway | 2011 |
Novel therapies for multiple myeloma.
Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Enzyme Inhibitors; Estradiol; Heterocyclic Compounds, 3-Ring; Humans; Multiple Myeloma; NF-kappa B; Oxides; Phthalazines; Protease Inhibitors; Protein-Tyrosine Kinases; Pyridines; Thalidomide | 2003 |
1 trial(s) available for vatalanib and Kahler Disease
| Article | Year |
|---|---|
Efficacy and tolerability of PTK787/ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemotherapy and autologous stem cell transplant.
Topics: Adult; Aged; Combined Modality Therapy; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Phthalazines; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Remission Induction; Stem Cell Transplantation; Survival Rate; Transplantation, Homologous; Treatment Outcome | 2010 |
2 other study(ies) available for vatalanib and Kahler Disease
| Article | Year |
|---|---|
Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Evaluation, Preclinical; Humans; Indoles; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Phthalazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Topics: Bone Marrow; Cell Adhesion; Cell Division; Cell Movement; Dexamethasone; Drug Synergism; Extracellular Matrix Proteins; Humans; Interleukin-6; Multiple Myeloma; Phosphorylation; Phthalazines; Proto-Oncogene Proteins c-kit; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3 | 2002 |